Peripheral effects of opioids in a model of intestinal inflammation in mice

Pharmacology

Volumn 53, Issue 6, 1996, Pages 340-350

  Pol, Olga ^a   Sanchez, Bernard ^a   Pnig, Margarita M ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Gastrointestinal transit; Opioid receptors; Opioids; Peripheral inflammation

Indexed keywords

17 METHYLMORPHINE; 17 METHYLNALOXONE; 3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; CHARCOAL; CROTON OIL; FENTANYL; KAPPA OPIATE RECEPTOR; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPIATE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; ENTERITIS; GASTROINTESTINAL TRANSIT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030464048     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139449     Document Type: Article

References (29)

1. Hylden JL, Thomas DA, Iadarola MJ. Nahin RL. Dubner R: Spinal opioid analgesic effects are enhanced in a model of unilateral in-flammation/hypcralgcsia: Possible involvement of noradrenergic mechanisms. EurJ Pharmacol 1991; 194:135-143.
2. Stein C: Peripheral mechanisms of opioid analgesia. Ancsth Analg 1993;76:182-191.
3. Stein C: The control of pain in peripheral tissue by opioids. N Engl J Med 1995:332:1685-1690.
4. Stanfa I-C. Sullivan AF, Dickenson AH: Alterations in neuronal excitability and the potency of spinal mu. delta and kappa opioids carrageen-in-induced inflammation. Pain 1992:50:345-354.
5. Stanfa LC. Dickenson AH: Cholc-cystokinin as a factor in the enhanced potency of spinal morphine following carragccnin inflammation. Br J Pharmacol 1993:108:967-973.
6. Pol O. Ferrer I. Puig MM: Diarrhoea associated with intestinal inflammation increases the potency of mu and delta opioids on the inhibition of gastrointestinal transit in mice. J Pharmacol Exp Ther 1994; 270:386-391.
7. Pol O, Planas E, Puig MM: Peripheral effects of naloxone in mice with acute diarrhoea associated with intestinal inflammation. J Pharmacol ExpTher 1995;272:1271-1276.
8. Nishiki K. Nishinaga K. Kudoh D. Iwai I: Croton oil-induced hemorrhoid model in rat: Comparison of anti-inflammatory activity of ditlu-cortolonc valerate with other glucocorticoids. Nippon Yakurigaku Zas-shi 1988:92:215-225.
9. Colorado A. Slama JT. Stavinoha WB: A new method for measuring auricular inflammation in the mouse. J Pharmacol Methods 1991: 26:73-77.
10. Shook JE. Lemcke PK. Gehrig CA, Hruby VJ, Burks TF: Antidiarrheal properties of supraspinal mu and delta and peripheral mu. delta and kappa opioid receptors: Inhibition of diarrhoea without constipation. J Pharmacol Exp Ther 1989:249:83-90.
11. Tavani A, Petrillo P. Laregina A, Sbacchi M: Role of peripheral mu. delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats. J Pharmacol ExpTher 1990:254:91-97.
12. Smith TW. Buchan P. Parsons DN. Wilkinson S: Peripheral antinociceptive effects of n-methyl morphine. Life Sci 1982:31:1205-1208.
13. Milne RJ, Coddington JM. Gamble GD: Quaternary naloxone blocks morphine analgesia in spinal but not intact rats. Neurosci Lett 1990:114: 259-264.
14. Chang KJ. Wei ET. Killian A. Chang JK: Potent morphiceptin analogs: Stnicture activity relationships and morphine-like activities. J Pharmacol ExpTher 1983:227:403-408.
15. Shaw JS. Carroll JA. Alcock P. Main BG: IC1-204448: A kappa-opioid agonist with limited access to the CNS. Br J Pharmacol 1989;96:986-992.
16. Ramabadran K. Bansinath M. Turndorf H. Puig MM: Stereospecific inhibition of gastrointestinal transit by kappa opioid agonist in mice. Eur J Pharmacol 1988:155: 329-331.
17. Ramabadran K. Bansinath M. Turndorf H, Puig MM: Hyperglv-caemia as a factor affecting kappa opiate agonist-induced inhibition on the gastrointestinal transit in mice. J Pharm Pharmacol 1989:41:496-498.
18. Tallarida RJ. Murray RB: Manual of Pharmacologic Calculations with Computer Programs. New York, Springer, 1986.
19. Megcns AA. Canters LL, Awoutcrs FH, Niemegeers CJ: Normalization of small intestinal propulsion with loperamide-like antidiarrheals in rats. Eur J Pharmacol 1990:178: 357-364.
20. Stewart JJ. Weisbrodt NW. Burks TF: Central and peripheral actions of morphine on intestinal transit. J Pharmacol Exp Ther 1978:205:547-555.
21. Porrcca F. Cowan A. Raffa RB. Tallarida RJ: Ketazocines and morphine: Effects on gastrointestinal transit after central and peripheral administration. Life Sci 1983:32: 1785-1790.
22. Koslo RJ. Vaught JL, Cowan A, Gmcrck DE, Porreca F: Intrathecal morphine slows gastrointestinal transit in rats. Eur J Pharmacol 1985:119:243-246.
23. Manara L. Bianchi G, Ferretti P, Tavani A: Inhibition of gastrointestinal transit by morphine in rats results primarily from direct drug action on gut opioid sites. J Pharmacol ExpTher 1986;237:945-949.
24. Kromer W: Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion. Pharmacol Rev 1988:40:121-162.
25. Gmerck DE, Cowan A, Woods JH: Independent central and peripheral mediation of morphine-induced in-hibiton of gastrointestinal transit in rats. J Pharmacol Exp Thcr 1986: 236:8-13.
26. Shook JE. Pelton JT. Hruby VJ. Burks TF: Peptide opioid antagonist separates peripheral and central opioid antitransit effects. J Pharmacol ExpTher 1987;243:492-500.
27. Barber A, Gottschlich R: Opioid agonist and antagonists: An evaluation of their peripheral actions in inflammation. Med Res Rev 1992:12:525-562.
28. Schulz R. Wiistcr M. Hcrt A: Centrally and peripherally mediated inhibition motility by opioids. Nau-nyn Schmiedebergs Arch Pharmacol 1979:308:255-260.
29. Handa BK. Lane A. Lord JAH. Morgan BA. Rance MJ. Smith CFC: Analogues of beta-I.PH 61-64 possessing selective agonists at mu-opiate receptors. Eur J Pharmacol 1981;70:531-540.